Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
36 pending office actions • 23 art units • 35 examiners • 0 of 36 (0%) have an AI response strategy ready • 24 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (6%) |
| §103 only | 12 (33%) |
| §112 only | 5 (14%) |
| Double-patenting only | 1 (3%) |
| Double-patenting + other | 4 (11%) |
| Multi-statute (no §101) | 12 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBOTT, KODYE LEE | 2 | 53.1% | +71.4% |
| MAHROUKA, WASSIM | 1 | 86.1% | +7.9% |
| WESTON, ALYSSA G | 1 | 59.8% | +50.9% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| YU, TIAN NMN | 1 | 55.1% | +20.4% |
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
| KIM, DANIELLE A | 1 | 37.1% | +56.3% |
| ABUZEINEH, HANAN ISAM | 1 | 53.2% | +54.3% |
| VALENCIA, JUAN C | 1 | 86.5% | +7.7% |
| MUI, CHRISTINE T | 1 | 78.3% | +19.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683412 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | HABTE, KAHSAY | — |
| 18558770 | THERMOCHEMICAL REACTOR AND PROCESS | VALENCIA, JUAN C | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17761677 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRYTHMOGENIC CARDIOMYOPATHY | REGLAS, GILLIAN CHELSEA | 19d overdue |
| 17793221 | DRUG ELUTING BIOMATERIALS | PRAGANI, RAJAN | 12d |
| 19101219 | Probe Pose Determination | MAHROUKA, WASSIM | — |
| 18701115 | GUIDE RNA AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | YU, TIAN NMN | — |
| 18559778 | SYNTHETIC RECEPTORS | ABUZEINEH, HANAN ISAM | — |
| 18552977 | USE OF MICROVESICLES FOR BENIGN COLORECTAL POLYPS AND COLORECTAL CANCER SCREENING | MUI, CHRISTINE T | — |
| 18269141 | TREATMENT FOR LYSINE DEGRADATION-ASSOCIATED DISORDERS | DACE DENITO, ALEXANDRA GERALDINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18505809 | COMPOSITIONS FOR THE TREATMENT OF A DISEASE OF THE URINARY TRACT AND TREATMENT OF A DISEASE INVOLVING THE INTRACELLULAR DELIVERY OF THE PARTICLE OR A MEDICAMENT CONTAINED THEREIN | KIM, DANIELLE A | 1d overdue |
| 18792799 | METHOD FOR ENHANCING THE SUPPRESSIVE PROPERTIES OF TREG CELLS | WESTON, ALYSSA G | — |
| 18701115 | GUIDE RNA AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | YU, TIAN NMN | — |
| 18559778 | SYNTHETIC RECEPTORS | ABUZEINEH, HANAN ISAM | — |
| 18552977 | USE OF MICROVESICLES FOR BENIGN COLORECTAL POLYPS AND COLORECTAL CANCER SCREENING | MUI, CHRISTINE T | — |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | ABBOTT, KODYE LEE | — |
| 18255444 | RETROVIRAL VECTORS | ABBOTT, KODYE LEE | — |
| Art Unit | Apps |
|---|---|
| 1632 | 4 |
| 1633 | 2 |
| 1643 | 2 |
| 3797 | 2 |
| 1634 | 2 |
| 1642 | 2 |
| 1631 | 2 |
| 1624 | 1 |
| 1613 | 1 |
| 1771 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19101219 | Probe Pose Determination | MAHROUKA, WASSIM | — | §101§103 | Non-Final OA | — | Pending | Feb 04, 2025 |
| 18792799 | METHOD FOR ENHANCING THE SUPPRESSIVE PROPERTIES OF TREG CELLS | WESTON, ALYSSA G | — | §102§103§112DP | Non-Final OA | — | Pending | Aug 02, 2024 |
| 18701115 | GUIDE RNA AND USES THEREOF | LIPPOLIS, ALEXANDRA ROSE | — | §102§103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18570947 | NUCLEIC ACID NANOPORE WITH ENHANCED SENSING FUNCTIONALITY | YU, TIAN NMN | — | §102§103§112 | Non-Final OA | — | Pending | Mar 18, 2024 |
| 18683412 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | HABTE, KAHSAY | 1624 | §112Other | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18505809 | COMPOSITIONS FOR THE TREATMENT OF A DISEASE OF THE URINARY TRACT AND TREATMENT OF A DISEASE INVOLVING THE INTRACELLULAR DELIVERY OF THE PARTICLE OR A MEDICAMENT CONTAINED THEREIN | KIM, DANIELLE A | 1613 | §103 | Final Rejection | 1d overdue | Pending | Nov 09, 2023 |
| 18559778 | SYNTHETIC RECEPTORS | ABUZEINEH, HANAN ISAM | 1633 | §102§103§112 | Non-Final OA | — | Pending | Nov 08, 2023 |
| 18558770 | THERMOCHEMICAL REACTOR AND PROCESS | VALENCIA, JUAN C | 1771 | §103 | Non-Final OA | — | Pending | Nov 03, 2023 |
| 18552977 | USE OF MICROVESICLES FOR BENIGN COLORECTAL POLYPS AND COLORECTAL CANCER SCREENING | MUI, CHRISTINE T | 1797 | §101§102§103§112 | Non-Final OA | — | Pending | Sep 28, 2023 |
| 18550739 | CD160 Binding Domain | NICKOL, GARY B | 1643 | §112 | Non-Final OA | — | Pending | Sep 15, 2023 |
| 18261411 | SUBJECT POSITIONING | BUI PHO, PASCAL M | 3798 | §103 | Final Rejection | — | Pending | Jul 13, 2023 |
| 18269141 | TREATMENT FOR LYSINE DEGRADATION-ASSOCIATED DISORDERS | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18258414 | A SYSTEM FOR POSITIONING A MEDICAL TOOL | ASGHAR, AMINAH | 3797 | §103 | Final Rejection | 86d overdue | Pending | Jun 20, 2023 |
| 17910686 | GENE THERAPY OF NIEMANN-PICK DISEASE TYPE C | ABBOTT, KODYE LEE | 1634 | §103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18267835 | POLYPEPTIDE | XIAO, YAN | 1642 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18255444 | RETROVIRAL VECTORS | ABBOTT, KODYE LEE | 1634 | §103 | Final Rejection | — | Pending | Jun 01, 2023 |
| 17915043 | ACTIVITY-DEPENDENT GENE THERAPY FOR NEUROLOGICAL DISORDERS | GROOMS, TIFFANY NICOLE | 1637 | §102§103§112DP | Non-Final OA | — | Pending | May 22, 2023 |
| 18194235 | ELECTROCARDIOGRAPHIC IMAGING SYSTEM AND METHOD | BROWN, HELENE CATHERINE | 3797 | §103 | Final Rejection | 28d overdue | Pending | Mar 31, 2023 |
| 18042899 | PRODUCTION OF INORGANIC SALTS | ZIMMER, ANTHONY J | 1736 | §103 | Final Rejection | 44d overdue | Pending | Feb 24, 2023 |
| 18005577 | PIEZOELECTRIC AND PIEZOCATALYTIC COMPOSITE MATERIAL, AND METHODS OF USING AND FORMING IT | BREWSTER, HAYDEN R | 1779 | §103 | Non-Final OA | 49d overdue | Pending | Jan 13, 2023 |
| 18011583 | THERAPEUTICS FOR THE TREATMENT OF FSHD | SAMSELL, RILLA MARIE | 1626 | §102§112DP | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18009945 | METHODS FOR DETECTING AND PREDICTING CANCER AND/OR CIN3 | KENNEDY, SARAH JANE | 1682 | DP | Final Rejection | 72d overdue | Pending | Dec 12, 2022 |
| 18047199 | GENE THERAPY FOR BARDET-BIEDL SYNDROME | MONTANARI, DAVID A | 1632 | §102§103 | Non-Final OA | — | Pending | Oct 17, 2022 |
| 17904388 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | MCMILLIAN, KARA RENITA | 1623 | §102§112Other | Non-Final OA | — | Pending | Aug 17, 2022 |
| 17819757 | END-EFFECTOR FOR ENDOSCOPIC SURGICAL INSTRUMENT | MULLINS, JESSICA LYNN | 3792 | §102§103 | Non-Final OA | — | Pending | Aug 15, 2022 |
| 17798796 | GENE THERAPY | SINGH, ANOOP KUMAR | 1632 | §112 | Non-Final OA | — | Pending | Aug 10, 2022 |
| 17759222 | ENGINEERED IMMUNE CELLS | GODDARD, LAURA B | 1642 | §103 | Non-Final OA | — | Pending | Jul 21, 2022 |
| 17793221 | DRUG ELUTING BIOMATERIALS | PRAGANI, RAJAN | 1614 | §102§103§112 | Final Rejection | 12d | Pending | Jul 15, 2022 |
| 17784836 | TIME-RESOLVED METHOD OF PROTEIN ANALYSIS | GZYBOWSKI, MICHAEL STANLEY | 1798 | §103 | Non-Final OA | — | Pending | Jun 13, 2022 |
| 17783167 | GENE THERAPY COMPOSITION AND TREATMENT FOR MYH7-LINKED CARDIOMYOPATHY | MOLOYE, TITILAYO | 1632 | §112 | Final Rejection | 16d | Pending | Jun 07, 2022 |
| 17780786 | TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION | INAM, SAHAR | 1633 | §112 | Final Rejection | — | Pending | May 27, 2022 |
| 17775172 | Extracellular Matrix Gels, and Organoid Cultures Comprising the Same | SCHUBERG, LAURA J | 1631 | §103 | Final Rejection | 31d overdue | Pending | May 06, 2022 |
| 17773103 | METHOD FOR THE PRODUCTION OF MÜLLER CELLS AND CELL PRODUCT | ZHU, JIANJIAN | 1631 | §103§112 | Non-Final OA | — | Pending | Apr 29, 2022 |
| 17761677 | GENE THERAPY COMPOSITION AND TREATMENT OF RIGHT VENTRICULAR ARRYTHMOGENIC CARDIOMYOPATHY | REGLAS, GILLIAN CHELSEA | 1632 | §103§112 | Final Rejection | 19d overdue | Pending | Mar 18, 2022 |
| 18299415 | METHOD OF TREATING CANCER WITH A BRCA1-ASSOCIATED PROTEIN 1 INHIBITOR AND A DEATH RECEPTOR LIGAND | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | — | Pending | Apr 12, 2023 |
| 17904393 | AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 | WELLS, LAUREN QUINLAN | 1622 | §112DP | Non-Final OA | 87d overdue | Pending | Aug 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial